EN
We strive to make patients-driven cellular immunotherapy innovation,
to transform cancer into a manageable condition — and ultimately cure it.
 
HomeNews and MediaCompany News
Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy
  • 0


On the cover: 

The transdifferentiation paths of erythroid precursor cells (EPCs) under the influence of tumor is delineated from Palantir algorithm‐based single-cell transcriptomic trajectory analysis (Long et al., 674–693), and embedded into artwork inspired by Wassily Kandinsky's “Composition 8.” As acquired “organs,” tumors exert a self-beneficial influence on the immune system by hijacking of erythropoiesis for myelopoiesis. Besides exacerbating anemia, CD45+ EPCs transdifferentiation generates myeloid cells that robustly curtail anti‐tumor immunity. Clinically, the abundance of these converted cells predicts immune tolerance in many human tumor types and resistance to immune checkpoint inhibitor treatment. Design and painting by Yijie Hou. Conceptual visualization by Qi-Jing Li and Bo Zhu.

 

https://www.cell.com/cancer-cell/current#closeFullCover
 



Copyright © 2019 TCR CURE Biopharma Technology Co., Ltd Powered by vancheer
About TCRCure
Research and Development
Product and Cinical trial
News and Media

Copyright © 2019 TCR CURE Biopharma Technology Co., Ltd Powered by vancheer